ANS02 / Avistone Biotech - LARVOL DELTA

ANS02, a Novel, Non-covalent, Brain-penetrant EGFR TKI, Overcomes Clinically Relevant Resistance Mutations and Demonstrates Broad Preclinical Activity in EGFR-Mutant NSCLC Models (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor